Fasting and Mediterranean diet for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether a special diet—longer nightly fasting plus a Mediterranean eating pattern—can help people with multiple myeloma or its early stages. If you qualify, you will be randomly assigned to start the diet right away or join a waitlist group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have MGUS, smoldering multiple myeloma, or newly diagnosed multiple myeloma and are starting treatment.
- You receive care at the Sylvester Cancer Center or University of Miami Health System.
- Your oncologist has given permission for you to join.
- You are not currently eating a Mediterranean diet or regularly fasting overnight.
- You have internet access on a device and are willing to try a diet change.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a plant-based diet can help people with newly diagnosed multiple myeloma who are receiving a standard 4-cycle drug combination (DRVd). Researchers want to see if changing what you eat might improve treatment results.
This study tests whether a plant-based diet and certain supplements can help people with smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). Participants will learn to cook plant-based recipes and track their meals using a phone app.
This study tests whether a Korean-style Mediterranean diet and tracking physical activity can help people with MGUS or smoldering multiple myeloma. Participants will follow the diet for 12 weeks and wear a device to measure their daily activity.
This trial tests whether a whole-food, plant-based eating pattern—plus supplements or placebo—can improve health outcomes in people with MGUS or smoldering multiple myeloma. You may be asked to follow specific recipes and stop certain supplements, so it helps to confirm you can stick with the plan.
This study tests a combination of three cancer drugs (belantamab mafodotin, bortezomib, and dexamethasone) in people with multiple myeloma who have had prior treatment and moderate liver function problems. The goal is to see if this combination works safely in patients whose cancer has come back or worsened.
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.